Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability.

OBJECTIVE To assess axonal damage and its contribution to disability at different stages of multiple sclerosis (MS). BACKGROUND Recent in vivo imaging and in situ pathologic studies have demonstrated that substantial axonal damage accompanies the inflammatory lesions of MS. However, the relation of axonal damage to the duration of MS and its contribution to disability at different stages of the disease remain poorly defined. DESIGN We performed proton magnetic resonance spectroscopic imaging in 88 patients with a wide range of clinical disability and disease duration to measure N-acetylaspartate (NAA, an index of axonal integrity) relative to creatine (Cr) in a large central brain volume that included mostly normal-appearing white matter on magnetic resonance imaging. RESULTS We observed that the NAA/Cr values were abnormally low in the early stages of MS, even before significant disability (measured using the Expanded Disability Status Scale [EDSS]) was evident clinically, and declined more rapidly with respect to EDSS at lower than at higher EDSS scores (P<.001). The correlation of NAA/Cr values with EDSS score was significantly (P<.03) stronger in patients with mild disability (EDSS score <5, Spearman rank order correlation = -0.54, P<.001) than in patients with more severe disability (EDSS score >/=5, Spearman rank order correlation = -0.1, P<.9). When similar analyses were performed in patients with MS grouped for duration of disease, the subgroup with early disease duration (<5 years) also showed central brain NAA/Cr resonance intensity ratios significantly lower than healthy controls (P<.001). CONCLUSION Cerebral axonal damage begins and contributes to disability from the earliest stages of the disease.

[1]  A. Członkowska,et al.  [Axonal degeneration in the pathogenesis of multiple sclerosis]. , 2002, Neurologia i neurochirurgia polska.

[2]  S G Waxman,et al.  Multiple sclerosis as a neuronal disease. , 2005, Archives of neurology.

[3]  G. B. Pike,et al.  Relating axonal injury to functional recovery in MS , 2000, Neurology.

[4]  R I Grossman,et al.  Total brain N-acetylaspartate , 2000, Neurology.

[5]  K. Bhakoo,et al.  In Vitro Expression of N‐Acetyl Aspartate by Oligodendrocytes , 2000, Journal of neurochemistry.

[6]  P M Matthews,et al.  Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis. , 2000, Archives of neurology.

[7]  G J Barker,et al.  Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup? , 1999, Journal of neurology, neurosurgery, and psychiatry.

[8]  R. Herndon,et al.  A longitudinal study of brain atrophy in relapsing multiple sclerosis , 1999, Neurology.

[9]  F Barkhof,et al.  Neuronal damage in T1‐hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy , 1999, Annals of neurology.

[10]  B D Trapp,et al.  Axonal pathology in multiple sclerosis: relationship to neurologic disability. , 1999, Current opinion in neurology.

[11]  Max S. Cynader,et al.  Axonal cytoskeleton changes in experimental optic neuritis , 1999, Brain Research.

[12]  R. Tarducci,et al.  Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. , 1999, Brain : a journal of neurology.

[13]  R. Rudick,et al.  Neurodegeneration in Multiple Sclerosis: Relationship to Neurological Disability , 1999 .

[14]  B. Stankoff,et al.  Eliprodil stimulates CNS myelination , 1999, Neurology.

[15]  Kenneth J. Smith,et al.  Demyelination: The Role of Reactive Oxygen and Nitrogen Species , 1999, Brain pathology.

[16]  C. Heldin,et al.  Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis. , 1998, Brain : a journal of neurology.

[17]  Robin Franklin,et al.  Axon loss in multiple sclerosis , 1998, The Lancet.

[18]  P M Matthews,et al.  Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. , 1998, Brain : a journal of neurology.

[19]  G. Barker,et al.  Spinal cord atrophy and disability in MS , 1998, Neurology.

[20]  N. Losseff,et al.  Measures of brain and spinal cord atrophy in multiple sclerosis. , 1998, Journal of neurology, neurosurgery, and psychiatry.

[21]  W. Brück,et al.  Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions , 1998, Multiple sclerosis.

[22]  F. Barkhof,et al.  Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. , 1998, Brain : a journal of neurology.

[23]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[24]  G. Wolswijk Chronic Stage Multiple Sclerosis Lesions Contain a Relatively Quiescent Population of Oligodendrocyte Precursor Cells , 1998, The Journal of Neuroscience.

[25]  J S Wolinsky,et al.  Serial proton magnetic resonance spectroscopic imaging, contrast‐enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis , 1998, Annals of neurology.

[26]  P. Matthews,et al.  Putting Magnetic Resonance Spectroscopy Studies in Context: Axonal Damage and Disability in Multiple Sclerosis , 1998, Seminars in neurology.

[27]  P M Matthews,et al.  Imaging axonal damage of normal-appearing white matter in multiple sclerosis. , 1998, Brain : a journal of neurology.

[28]  A. Compston Future Options for Therapies to Limit Damage and Enhance Recovery , 1998, Seminars in neurology.

[29]  G. Barker,et al.  1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis , 1997, Journal of neurology, neurosurgery, and psychiatry.

[30]  S. Waxman,et al.  Distribution of sodium channels in chronically demyelinated spinal cord axons: immunoultrastructural localization and electrophysiological observations. Brain Research 544 (1991) 59-70. , 1997, Brain research.

[31]  M. Rovaris,et al.  A Longitudinal Magnetic Resonance Imaging Study of the Cervical Cord in Multiple Sclerosis , 1997, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[32]  V. Perry,et al.  Axonal damage in acute multiple sclerosis lesions. , 1997, Brain : a journal of neurology.

[33]  R. Barker,et al.  Proton magnetic resonance spectroscopy in a pathologically confirmed acute demyelinating lesion , 1997, Journal of Neurology.

[34]  S. Waxman Molecular remodeling of neurons in multiple sclerosis: what we know, and what we must ask about brain plasticity in demyelinating diseases. , 1997, Advances in neurology.

[35]  Jullie W Pan,et al.  Evaluation of multiple sclerosis by 1H spectroscopic imaging at 4.1 T , 1996, Magnetic resonance in medicine.

[36]  P. Matthews,et al.  Chemical pathology of acute demyelinating lesions and its correlation with disability , 1995, Annals of neurology.

[37]  A. Thompson,et al.  Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. , 1995, Brain : a journal of neurology.

[38]  P. Matthews,et al.  Reversible decreases in N‐acetylaspartate after acute brain injury , 1995, Magnetic resonance in medicine.

[39]  Jia Newcombe,et al.  High Resolution Proton NMR Spectroscopy of Multiple Sclerosis Lesions , 1995, Journal of neurochemistry.

[40]  G. Fein,et al.  Biochemical alterations in multiple sclerosis lesions and normal‐appearing white matter detected by in vivo 31P and 1H spectroscopic imaging , 1994, Annals of neurology.

[41]  W. Mcdonald RACHELLE FISHMAN-MATTHEW MOORE LECTURE: The Pathological and Clinical Dynamics of Multiple Sclerosis , 1994, Journal of neuropathology and experimental neurology.

[42]  D. Gadian,et al.  Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[43]  R de Beer,et al.  Application of time‐domain fitting in the quantification of in vivo 1H spectroscopic imaging data sets , 1992, NMR in biomedicine.

[44]  J. Coyle,et al.  Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies , 1991, Neuroscience.

[45]  M. Lazdunski,et al.  Increase of sodium channels in demyelinated lesions of multiple sclerosis , 1991, Brain Research.

[46]  W. Mcdonald,et al.  The longstanding MS lesion. A quantitative MRI and electron microscopic study. , 1991, Brain : a journal of neurology.

[47]  S. Waxman,et al.  Distribution of sodium channels in chronically demyelinated spinal cord axons: immuno-ultrastructural localization and electrophysiological observations , 1991, Brain Research.

[48]  J. Neale,et al.  Immunohistochemical localization of N-acetylaspartate in rat brain. , 1991, Neuroreport.

[49]  P M Matthews,et al.  Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: Assessment of the load of disease , 1990, Magnetic resonance in medicine.

[50]  William H. Oldendorf,et al.  N-Acetyl-L-Aspartic acid: A literature review of a compound prominent in 1H-NMR spectroscopic studies of brain , 1989, Neuroscience & Biobehavioral Reviews.

[51]  D Matthaei,et al.  1H NMR chemical shift selective (CHESS) imaging. , 1985, Physics in medicine and biology.

[52]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[53]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.